Precision Therapy in NSCLC: Pharmacist Perspectives on Testing Strategies and Biomarker-Driven Treatment Approaches
Presented by CEC Oncology and supported through an independent educational grant from AstraZeneca.
This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.
- Review the most recent molecular testing guidelines for non-small cell lung cancer (NSCLC), including clinically relevant biomarkers, recommended testing modalities, and implications for currently available and evolving treatments.
- Examine targeted therapies currently approved for NSCLC and appraise biomarker-driven approaches to selection and sequencing of therapy.
- Using a case-based approach, evaluate adaptive strategies pharmacists can employ to expand the uptake of guideline-recommended biomarker testing and ensure the appropriate selection of targeted therapy based on patient- and biomarker-specific factors.
Josiah D. Land, PharmD, BCOP
Clinical Pharmacy Specialist
Thoracic Medical Oncology Team
Memorial Sloan Kettering Cancer Center
New York, New York
Originally from Lake Charles, LA, Dr. Land received his BS in Biology from McNeese State University in Lake Charles and his PharmD from the University of Louisiana at Monroe in Monroe, LA. After pharmacy school, he completed a PGY1 Pharmacy Residency at The University of Texas MD Anderson Cancer Center in Houston, TX followed by a PGY2 Oncology Pharmacy Residency at Memorial Sloan Kettering Cancer Center in New York, NY. Dr. Land is currently the Clinical Pharmacy Specialist for the Thoracic Medical Oncology Service at Memorial Sloan Kettering Cancer Center, New York, NY. He is a Board Certified Oncology Pharmacist (BCOP) through the Board of Pharmacy Specialties (BPS).
Zofia Piotrowska, MD, MHS
Instructor of Medicine
Harvard Medical School
Assistant in Medicine
Massachusetts General Hospital
Dr. Piotrowska is an attending thoracic medical oncologist at Massachusetts General Hospital and Instructor of Medicine at Harvard Medical School. Her research is focused on improving therapies for EGFR-mutant lung cancers. Dr. Piotrowska received her Medical Degree from Yale University School of Medicine and trained in internal medicine at Brigham and Women’s Hospital and in hematology/oncology at Dana Farber Cancer Institute and Massachusetts General Hospital.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Joan B. Fowler, PharmD, BCPS—has no relevant financial relationships to disclose in relation to the content of this activity.
Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
Josiah D. Land, PharmD, BCOP— has no relevant financial relationships to disclose in relation to the content of this activity.
Zofia Piotrowska, MD, MHS—has disclosed that she is a consultant for AstraZeneca, Genentech, Lilly Incyte, and Medtronic; and she receives grant/research support from AstraZeneca, Novartis, Spectrum, Takeda, and Tesaro.
Bryan C. Taylor, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This application-based activity is approved for 1.0 contact hour (0.01 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-011-H01-P).
- 1.00 ACPE PharmacyIn support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This knowledge-based activity is approved for 1.00 contact hour (0.1 CEUs) of continuing pharmacy education credit JA0007101-0000-20-011-H01-P
- 1.00 Participation